We are live on
!
Find out more
VP
venBio Partners Portfolio holdings
AUM
$281M
1-Year Est. Return
261.03%
This Fund
S&P 500
This Quarter
Est. Return
-11.09%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$171M
AUM Growth
-$23.6M
(-12%)
Cap. Flow
+$3.84M
Cap. Flow
% of AUM
2.25%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
3
Closed
–
Top Buys
| 1 |
Lyell Immunopharma
LYEL
|
+$7.04M |
Top Sells
| 1 |
Harmony Biosciences
HRMY
|
+$2.59M |
| 2 |
ALMS
Alumis Inc
ALMS
|
+$387K |
| 3 |
SLRN
ACELYRIN
SLRN
|
+$223K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pharvaris
PHVS
$2.35B
| $82.2M | 48.17% |
4,289,304
| – | – |
|
|
ALMS
2
Alumis Inc
ALMS
$3.47B
| $21.9M | 12.83% |
2,787,398
-38,650
| -1% | -$387K |
|
|
3
Harmony Biosciences
HRMY
$1.94B
| $18.6M | 10.87% |
539,194
-75,400
| -12% | -$2.59M |
|
4
ALX Oncology
ALXO
$279M
| $16.2M | 9.49% |
9,699,925
| – | – |
|
|
ARTV
5
Artiva Biotherapeutics
ARTV
$439M
| $15.3M | 8.98% |
1,519,971
| – | – |
|
|
SLRN
6
DELISTED
ACELYRIN
SLRN
| $12M | 7% |
3,806,410
-46,060
| -1% | -$223K |
|
|
7
Lyell Immunopharma
LYEL
$340M
| $4.55M | 2.66% |
+355,110
| New | +$7.04M |
|
Similar funds
OCWP
FFP
BDA
PHC
OFCM
SA
ACC
NRCM